Weekly Digest - June 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - June 2024
12 June 2024: OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
- OBI Pharma has initiated a Phase 1/2 clinical trial for OBI-992, an ADC targeting TROP2, in patients with advanced solid tumors
- The trial’s goal is to evaluate safety, pharmacokinetics, and initial efficacy of OBI-992 in various cancers, including NSCLC, SCLC, and GC
- OBI-992 offers advantages like high stability, potent tumor-killing effects, and potential to combat drug resistance compared to other TROP2 ADCs
- OBI-992 utilizes a unique hydrophilic linker, demonstrating strong antitumor activity in preclinical models. OBI Pharma holds commercial rights globally, except in China
